Parkinson's researchers might be chasing the wrong culprit

03/21/2013 | Bloomberg

Alnylam Pharmaceuticals, Elan, NeuroPhage Pharmaceuticals and Prana Biotechnology are among the drugmakers developing therapies that focus on reducing alpha-synuclein in the brains of Parkinson's disease patients, but new research associates low levels of the protein with worsening symptoms. Parkinson's patients who had the lowest production of alpha-synuclein had a 23% higher risk of developing dementia or becoming disabled than patients with the highest levels, researchers reported at an American Academy of Neurology meeting.

View Full Article in:

Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX